Query

Active Filters

  • (-) PSI Laboratories = Center for Radiopharmaceutical Sciences CRS
  • (-) Journals ≠ Journal of Nuclear Medicine
Search Results 1 - 20 of 123

Pages

  • CSV Spreadsheet
  • Excel Spreadsheet
  • RSS Feed
Select Page
Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity
Deberle, L. M., Benešová, M., Umbricht, C. A., Borgna, F., Büchler, M., Zhernosekov, K., … Müller, C. (2020). Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity. Theranostics, 10(4), 1678-1693. https://doi.org/10.7150/thno.40482
The A/T/N model applied through imaging biomarkers in a memory clinic
Dodich, A., Mendes, A., Assal, F., Chicherio, C., Rakotomiaramanana, B., Andryszak, P., … Garibotto, V. (2020). The A/T/N model applied through imaging biomarkers in a memory clinic. European Journal of Nuclear Medicine and Molecular Imaging, 47(2), 247-255. https://doi.org/10.1007/s00259-019-04536-9
Biodistribution of site-specific PEGylated fibroblast growth factor-2
Lühmann, T., Gutmann, M., Moscaroli, A., Raschig, M., Béhé, M., & Meinel, L. (2020). Biodistribution of site-specific PEGylated fibroblast growth factor-2. ACS Biomaterials Science & Engineering, 6(1), 425-432. https://doi.org/10.1021/acsbiomaterials.9b01248
L1 cell adhesion molecule confers radioresistance to ovarian cancer and defines a new cancer stem cell population
Terraneo, N., Jacob, F., Peitzsch, C., Dubrovska, A., Krudewig, C., Huang, Y. L., … Grünberg, J. (2020). L1 cell adhesion molecule confers radioresistance to ovarian cancer and defines a new cancer stem cell population. Cancers, 12(1), 217 (17 pp.). https://doi.org/10.3390/cancers12010217
Influence of size and charge of unstructured polypeptides on pharmacokinetics and biodistribution of targeted fusion proteins
Brandl, F., Merten, H., Zimmermann, M., Béhé, M., Zangemeister-Wittke, U., & Plückthun, A. (2019). Influence of size and charge of unstructured polypeptides on pharmacokinetics and biodistribution of targeted fusion proteins. Journal of Controlled Release, 307, 379-392. https://doi.org/10.1016/j.jconrel.2019.06.030
Measurement of the <sup>43</sup>Sc production cross-section with a deuteron beam
Carzaniga, T. S., van der Meulen, N. P., Hasler, R., Kottler, C., Peier, P., Türler, A., … Braccini, S. (2019). Measurement of the 43Sc production cross-section with a deuteron beam. Applied Radiation and Isotopes, 145, 205-208. https://doi.org/10.1016/j.apradiso.2018.12.031
Internal radiation dosimetry of a <sup>152</sup>Tb-labeled antibody in tumor-bearing mice
Cicone, F., Gnesin, S., Denoël, T., Stora, T., van der Meulen, N. P., Müller, C., … Prior, J. O. (2019). Internal radiation dosimetry of a 152Tb-labeled antibody in tumor-bearing mice. EJNMMI Research, 9, 53 (10 pp.). https://doi.org/10.1186/s13550-019-0524-7
Production and characterization of no-carrier-added <sup>161</sup>Tb as an alternative to the clinically-applied <sup>177</sup>Lu for radionuclide therapy
Gracheva, N., Müller, C., Talip, Z., Heinitz, S., Köster, U., Zeevaart, J. R., … van der Meulen, N. P. (2019). Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapy. EJNMMI Radiopharmacy and Chemistry, 4, 12 (16 pp.). https://doi.org/10.1186/s41181-019-0063-6
L1CAM. Ein vielversprechendes Zellmembranprotein für therapeutische Interventionen
Grünberg, J., & Terraneo, N. (2019). L1CAM. Ein vielversprechendes Zellmembranprotein für therapeutische Interventionen. Leading Opinions Hämatologie & Onkologie.
Recent progress in allosteric modulators for GluN2A subunit and development of GluN2A-selective nuclear imaging probes
He, Y., Mu, L., Ametamey, S. M., & Schibli, R. (2019). Recent progress in allosteric modulators for GluN2A subunit and development of GluN2A-selective nuclear imaging probes. Journal of Labelled Compounds and Radiopharmaceuticals, 62(8), 552-560. https://doi.org/10.1002/jlcr.3744
High‐resolution SPECT imaging of stimuli‐responsive soft microrobots
Iacovacci, V., Blanc, A., Huang, H., Ricotti, L., Schibli, R., Menciassi, A., … Nelson, B. J. (2019). High‐resolution SPECT imaging of stimuli‐responsive soft microrobots. Small, 15(34), 1900709 (7 pp.). https://doi.org/10.1002/smll.201900709
Exendin-4 analogs in insulinoma theranostics
Jansen, T. J. P., van Lith, S. A. M., Boss, M., Brom, M., Joosten, L., Béhé, M., … Gotthardt, M. (2019). Exendin-4 analogs in insulinoma theranostics. Journal of Labelled Compounds and Radiopharmaceuticals, 62(10), 656-672. https://doi.org/10.1002/jlcr.3750
Comparison of desferrioxamine and NODAGA for the gallium-68 labeling of exendin-4
Kaeppeli, S. A. M., Schibli, R., Mindt, T. L., & Behe, M. (2019). Comparison of desferrioxamine and NODAGA for the gallium-68 labeling of exendin-4. EJNMMI Radiopharmacy and Chemistry, 4(1), 9 (11 pp.). https://doi.org/10.1186/s41181-019-0060-9
Exendin-4 derivatives with an albumin-binding moiety show decreased renal retention and improved GLP-1 receptor targeting
Kaeppeli, S. A. M., Jodal, A., Gotthardt, M., Schibli, R., & Behe, M. (2019). Exendin-4 derivatives with an albumin-binding moiety show decreased renal retention and improved GLP-1 receptor targeting. Molecular Pharmaceutics, 16(9), 3760-3769. https://doi.org/10.1021/acs.molpharmaceut.9b00271
Concentration‐dependent effects of dutasteride on prostate‐specific membrane antigen (PSMA) expression and uptake of <sup>177</sup>Lu‐PSMA‐617 in LNCaP cells
Kranzbühler, B., Salemi, S., Umbricht, C. A., Deberle, L. M., Müller, C., Burger, I. A., … Eberli, D. (2019). Concentration‐dependent effects of dutasteride on prostate‐specific membrane antigen (PSMA) expression and uptake of 177Lu‐PSMA‐617 in LNCaP cells. Prostate, 79(12), 1477-1483. https://doi.org/10.1002/pros.23868
Combination of proton therapy and radionuclide therapy in mice: preclinical pilot sudy at the Paul Scherrer Institute
Müller, C., De Prado Leal, M., Dominietto, M. D., Umbricht, C. A., Safai, S., Perrin, R. L., … Lomax, A. J. (2019). Combination of proton therapy and radionuclide therapy in mice: preclinical pilot sudy at the Paul Scherrer Institute. Pharmaceutics, 11(9), 450 (13 pp.). https://doi.org/10.3390/pharmaceutics11090450
Preclinical investigations and first-in-human application of <sup>152</sup>Tb-PSMA-617 for PET/CT imaging of prostate cancer
Müller, C., Singh, A., Umbricht, C. A., Kulkarni, H. R., Johnston, K., Benešová, M., … Baum, R. P. (2019). Preclinical investigations and first-in-human application of 152Tb-PSMA-617 for PET/CT imaging of prostate cancer. EJNMMI Research, 9(1), 68 (10 pp.). https://doi.org/10.1186/s13550-019-0538-1
Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer
Müller, C., Umbricht, C. A., Gracheva, N., Tschan, V. J., Pellegrini, G., Bernhardt, P., … van der Meulen, N. P. (2019). Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 46(9), 1919-1930. https://doi.org/10.1007/s00259-019-04345-0
Targeted <sup>64</sup>Cu-labeled gold nanoparticles for dual imaging with positron emission tomography and optical imaging
Pretze, M., van der Meulen, N.  P., Wängler, C., Schibli, R., & Wängler, B. (2019). Targeted 64Cu-labeled gold nanoparticles for dual imaging with positron emission tomography and optical imaging. Journal of Labelled Compounds and Radiopharmaceuticals, 62(8), 471-482. https://doi.org/10.1002/jlcr.3736
New <sup>55</sup>Co-labeled albumin-binding folate derivatives as potential PET agents for folate receptor imaging
Radford, L. L., Fernandez, S., Beacham, R., Sayed, R. E., Farkas, R., Benešová, M., … Lapi, S. E. (2019). New 55Co-labeled albumin-binding folate derivatives as potential PET agents for folate receptor imaging. Pharmaceuticals, 12(4), 166 (12 pp.). https://doi.org/10.3390/ph12040166
 

Pages